Pharmaceutical launch managers specializing in lupus now have a resource that aligns with their need for agility and speed in generating insights for decision making and ancillary solution development.
CELEBRATION, FL, August 29, 2024. RP Insights LLC is excited to announce the launch of Lupus Agile 10-10, a new research service that will accelerate development of patient support and messaging assets in the lupus therapeutic space. The RP Insights team has been working diligently this year to identify resources, methodologies, and approaches that can provide pharmaceutical product teams an edge over potential competitors when it comes to fully validated solutions, all within record speed time.
Through collaboration with our partners, internal stakeholders, and brand teams, this service will set the standard for agile ancillary asset development within an industry where sequential, regulatorily established processes are the norm.
This solution can benefit the dozens of teams supporting new therapies at different development stages for the treatment of systemic lupus erythematosus (SLE), from oral treatments, to biologics, to CAR T cell therapy.
How it works:
- A panel of systemic lupus erythematosus (SLE) patients and rheumatologists is ready to share their opinion within short notice
- From client approvals to insights presentation, projects take two to four weeks
- Insights are generated alongside the qualitative data gathering process
- Projects allow for interim checks for question and stimuli adjustments
RP Insights is aligned with the goal of brand, commercialization, and product teams to improve patients lives. But most of all, we are inspired by the resiliency of patients with lupus and the hard work of the specialists that coordinate their treatment
For additional information, please contact:
Raul Perez, PhD MBA
+1 407 809 4239
About RP Insights LLC
RP Insights is a market research consultancy with a strong focus on healthcare insights. We have experience in rheumatoid conditions and rare diseases. We possess in-house multi-language capabilities (English, French, Spanish, and Portuguese). We interview patients, nurses, and physicians to inform development of treatment start and maintenance strategies. We have experience in drug administration device user feedback, preference, and acceptability studies. We have experience in close to 20 therapeutic areas.
SOURCE: RP Insights LLC
